Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02949791
Other study ID # AIRC-2013-144445
Secondary ID
Status Completed
Phase Phase 2
First received October 7, 2016
Last updated February 21, 2018
Start date December 2014
Est. completion date November 2017

Study information

Verified date February 2018
Source Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is a promising therapy for peritoneal carcinomatosis (PC) of various origins. Rather than the pharmacokinetic advantage, the uptake of chemotherapy by tumor tissue has been proposed as the best pharmacologic endpoint to assure the efficacy of HIPEC.

The primary endpoints of the present phase II randomized study are to test whether the increased intra abdominal pressure (IAP) during HIPEC could:

- enhance the penetration of cisplatin into the residual neoplastic and normal tissues;

- elicit changes on pharmacokinetic advantage of cisplatin.

Secondary endpoints are to evaluate the:

- impact of high IAP on intraoperatory hemodynamic and respiratory parameters;

- impact on short-term surgical outcomes (in hospital stay, morbidity, mortality).

Patients affected by PC from colorectal cancer or pseudomyxoma peritonei, submitted to complete cytoreduction (residual disease <2.5mm) would be eligible for the study. HIPEC will be performed using closed abdomen technique and cisplatin + mitomycin-C. Patients will be randomly assigned to HIPEC with low IAP (8-12 mmHg) or high IAP (18-22 mmHg). IAP will be measured using bladder catheter. High IAP will be obtained increasing the volume of perfusate.

Thirty-eight patients (19 in each study groups) will be enrolled in 30 months. The randomized groups will be stratified according to tumor type.


Description:

Patients affected by peritoneal metastasis from colorectal cancer or pseudomyxoma peritonei, submitted to complete cytoreduction (residual disease <2.5mm) would be eligible for the study. Residual and resectable tumour nodules of 0.5 to 1.0 cm will be left behind after the cytoreduction and they will be collected at the end of HIPEC for the purpose of this study. HIPEC will be performed using closed abdomen technique and cisplatin (42mg/L of perfusate) + mitomycin-C (3.3mg/m2/L of perfusate) for 60 minutes, at 42.5°C. Patients will be randomly assigned to HIPEC with low IAP (8-12 mmHg) or high IAP (18-22 mmHg). IAP will be measured using bladder catheter. Patients of high IAP group will be strictly monitored during the perfusion regarding hemodynamic/respiratory parameters. During the HIPEC, perfusate and blood samples will be collected every 10 minutes. Additional samples of arterial blood will be collected at 70, 90,120,180 and 240 minutes. After the completion of HIPEC residual tumor tissues, normal peritoneum and muscular fascia will be sampled for determination of cisplatin concentration.

Blood samples will be immediately centrifuged to separate plasma. An aliquot of plasma will be stored at -30°C for total platinum determination. Another aliquot will be ultrafiltered by centrifugation through a membrane with a cut-off 5000 Da for ultrafilterable platinum determination. The ultrafiltrate will be stored at -30°C until analysis.

Perfusate samples will follow the same procedure of blood samples. Tissues samples will be stored at -80°C until analysis. Platinum determination will be performed using an Inductive Coupled Plasma Mass Spectrometry (ICP-MS) system by Thermo Scientific after preparing calibration curves with atomic platinum. Fluid samples simply dilute before ICP-MS examination while tissues will be desiccated, digested with a mixture of nitric acid and oxygen water, and evaporated to dryness prior to determination.

The investigators will compare the following outcomes between the study groups: tumor tissue concentration of cisplatin; the area under the curve (AUC) ratio of perfusate UF concentration of cisplatin times time to plasma UF concentration times time; in-hospital stay; systemic toxicity (NCI-CTCAE.v3), morbidity, and mortality.

Thirty eight patients (19 in each group) would be needed to detect an increase cisplatin concentration of 20 ng/mg of tumor tissue if patients are submitted to high-IAP during HIPEC, assuming alfa=0.05 and power=0.90 and standard deviation of 15 ng. Accrual time will be 30 months. The randomized groups will be stratified according to tumor type.


Recruitment information / eligibility

Status Completed
Enrollment 38
Est. completion date November 2017
Est. primary completion date November 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

1. Histological diagnosis of primary peritoneal carcinomatosis from colorectal origin or pseudomyxoma peritonei

2. Patients submitted to complete cytoreduction with residual tumor <2.5 mm

3. Patients at the end of cytoreduction should present the laboratorial and hemodynamic parameters set as followings:

- Mean arterial pressure > 65 mmHg

- Heart rate: < 100 bpm

- Central venous pressure > 4 mmHg

- Cardiac index > 2.2

- Central venous oxygen saturation (ScvO2) > 72%, and

- Haemoglobin > 8.0 gr/dl.

4. Informed consent signed from the patient before the procedure.

Exclusion Criteria:

- Severe hemodynamic and/or respiratory instability after the cytoreduction that precludes HIPEC.

Study Design


Intervention

Procedure:
Cytoreductive surgery
Maximal surgical effort to obtain a minimal residual disease of less than 2.5 mm
Other:
Low Intra abdominal pressure HIPEC
Hyperthermic intraperitoneal chemotherapy using closed modality and intra abdominal pressure of 8-12 mmHg
High Intra abdominal pressure HIPEC
Hyperthermic intraperitoneal chemotherapy using closed modality and intra abdominal pressure of 18-22 mmHg

Locations

Country Name City State
Italy Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Milano MI

Sponsors (2)

Lead Sponsor Collaborator
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Associazione Italiana per la Ricerca sul Cancro

Country where clinical trial is conducted

Italy, 

References & Publications (6)

Esquis P, Consolo D, Magnin G, Pointaire P, Moretto P, Ynsa MD, Beltramo JL, Drogoul C, Simonet M, Benoit L, Rat P, Chauffert B. High intra-abdominal pressure enhances the penetration and antitumor effect of intraperitoneal cisplatin on experimental peritoneal carcinomatosis. Ann Surg. 2006 Jul;244(1):106-12. — View Citation

Facy O, Al Samman S, Magnin G, Ghiringhelli F, Ladoire S, Chauffert B, Rat P, Ortega-Deballon P. High pressure enhances the effect of hyperthermia in intraperitoneal chemotherapy with oxaliplatin: an experimental study. Ann Surg. 2012 Dec;256(6):1084-8. doi: 10.1097/SLA.0b013e3182582b38. — View Citation

Facy O, Combier C, Poussier M, Magnin G, Ladoire S, Ghiringhelli F, Chauffert B, Rat P, Ortega-Deballon P. High pressure does not counterbalance the advantages of open techniques over closed techniques during heated intraperitoneal chemotherapy with oxaliplatin. Surgery. 2015 Jan;157(1):72-8. doi: 10.1016/j.surg.2014.06.006. Epub 2014 Jul 12. — View Citation

Jacquet P, Stuart OA, Chang D, Sugarbaker PH. Effects of intra-abdominal pressure on pharmacokinetics and tissue distribution of doxorubicin after intraperitoneal administration. Anticancer Drugs. 1996 Jul;7(5):596-603. — View Citation

Rossi CR, Foletto M, Mocellin S, Pilati P, De SM, Deraco M, Cavaliere F, Palatini P, Guasti F, Scalerta R, Lise M. Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis: phase I study. Cancer. 2002 Jan 15;94(2):492-9. — View Citation

Van der Speeten K, Stuart OA, Sugarbaker PH. Pharmacokinetics and pharmacodynamics of perioperative cancer chemotherapy in peritoneal surface malignancy. Cancer J. 2009 May-Jun;15(3):216-24. doi: 10.1097/PPO.0b013e3181a58d95. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Tumor tissue concentration of cisplatin residual neoplastic tissue concentration of cisplatin measured in ng/mg collected within 15 minutes after the completion of HIPEC
Primary Normal tissue concentration of cisplatin tissue concentration of cisplatin measured in ng/mg in peritoneum of mesentery and rectal muscle fascia collected within 15 minutes after the completion of HIPEC
Secondary Pharmacokinetic advantage Peritoneal to plasma area under the curve (AUC) ratio of ultrafiltrated cisplatin concentrations During the HIPEC up to 1 hour from the completion of perfusion
Secondary Pharmacokinetic advantage 2 Peritoneal to plasma area under the curve (AUC) ratio of total protein bound cisplatin concentrations During the HIPEC up to 1 hour from the completion of perfusion
Secondary Impact of high intra-abdominal pressure on anesthesiologic parameters 1 Mean arterial pressure (mmHg) Intraoperative phase
Secondary Impact of high intra-abdominal pressure on anesthesiologic parameters 2 Heart rate (beats per minute) Intraoperative phase
Secondary Impact of high intra-abdominal pressure on anesthesiologic parameters 3 Central venous pressure (mmHg) Intraoperative phase
Secondary Impact of high intra-abdominal pressure on anesthesiologic parameters 4 Cardiac index Intraoperative phase
Secondary Impact of high intra-abdominal pressure on anesthesiologic parameters 5 Arterial oxygen saturation (PaO2) Intraoperative phase
Secondary Impact of high intra-abdominal pressure on anesthesiologic parameters 6 Central venous oxygen saturation (ScvO2) Intraoperative phase
Secondary Impact of intraoperative high intra-abdominal pressure on short-term surgical outcomes 1 Surgical complications (NCI CTCAEv3) within 30 days after surgery
Secondary Impact of intraoperative high intra-abdominal pressure on short-term surgical outcomes 2 Systemic toxicity (NCI CTCAEv3) within 30 days after surgery
Secondary Impact of intraoperative high intra-abdominal pressure on short-term surgical outcomes 3 Mortality within 30 days after surgery
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Completed NCT00098787 - Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05425940 - Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer Phase 3
Suspended NCT04595604 - Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery. N/A
Completed NCT03414125 - Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening N/A
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT03874026 - Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03167125 - Participatory Research to Advance Colon Cancer Prevention N/A
Completed NCT03181334 - The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation N/A
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Recruiting NCT05568420 - A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Completed NCT02876224 - Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Phase 1
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A